TABLE 1.
Characteristics of the trials investigated.
| Study | Treatment | Duration, w | Number of baseline | Number of follow-up | Men, % | Mean age, y | Duration of DM a , y | HbA1 c , % | BMI b , kg/m2 | Weight, kg |
|---|---|---|---|---|---|---|---|---|---|---|
| Kuhadiya et al. (2016) | Liraglutide | 12 | 72 | 63 | 44.4 | 44.8 | 24.1 | 7.6 | 28.8 | 84.8 |
| Mathieu et al. (2016) | Liraglutide | 52 | 1389 | 1389 | 47.7 | 43.7 | 21.4 | 8.2 | 29.5 | 86.2 |
| Ahren et al. (2016) | Liraglutide | 26 | 831 | 831 | 46.0 | 43.2 | 21.1 | 8.1 | 28.9 | 83.9 |
| Dejgaard et al., 2016 | Liraglutide | 24 | 100 | 100 | 65 | 48.0 | 22.5 | 8.7 | 30.1 | 93.7 |
| Johansen et al. 2020 | Exenatide | 26 | 108 | 105 | 72.4 | 50.3 | 21.1 | 8.3 | 28.3 | 87.7 |
| Dejgaard et al. (2021) | Liraglutide | 26 | 44 | 44 | 31.8 | 46.5 | 20.5 | 8.2 | 29.5 | 86.5 |
| Pozzilli et al. 2020 | Albiglutide | 52 | 61 | 61 | 55.7 | 22.5 | NA c | 7.3 | 22.4 | 66.8 |
| Frandsen et al. 2015 | Liraglutide | 12 | 40 | 36 | 66.7 | 37.8 | 19.0 | 8.8 | 23.5 | 75.4 |
| Herold et al. 2020 | Exenatide er | 24 | 79 | 79 | 31.6 | 36.1 | 19.6 | 7.6 | 29.4 | 83.9 |
| Ghanim et al. 2020 | Liraglutide | 26 | 84 | 64 | 37.5 | 46.2 | NA c | 7.9 | 31.7 | 89.6 |
| Brock et al. 2019 | Liraglutide | 26 | 48 | 39 | 79.5 | 50.5 | 31.5 | 8.2 | 29.0 | 92.5 |
a
DM, diabetes mellitus.
b
BMI, body mass index.
c
NA, not available.